Daiichi Sankyo lines up a $900M deal for rights to a cholesterol drug looking to disrupt a blockbuster market

While Esperion’s investors have been through a roller coaster of reactions on whether or not the FDA was willing to accept LDL lowering as a suitable biomarker for an approval — ahead of an outcomes study — the CEO says that European regulators have consistently nodded their approval throughout the development process.